HLA Class II as Potential Target Antigen on Malignant B Cells for Therapy With Bispecific Antibodies in Combination With Granulocyte Colony-Stimulating Factor

Overview of attention for article published in Blood, May 1996

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

patent: 37 patents

Readers on

mendeley: 26 Mendeley

So far, Altmetric has seen 37 patents that reference this research output.

POLYPEPTIDE

Application WO-2022129910-A1

World Intellectual Property Organisation (WIPO)

23 Jun 2022

CD3 binding polypeptides

Grant US-11352426-B2

United States of America

07 Jun 2022

Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies

Grant US-11180559-B2

United States of America

23 Nov 2021

Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic…

Grant US-10988539-B2

United States of America

27 Apr 2021

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 33 additional patents.